Edwards Lifesciences (NYSE:EW) Given New $90.00 Price Target at Barclays

Edwards Lifesciences (NYSE:EW - Get Free Report) had its target price upped by Barclays from $88.00 to $90.00 in a research note issued to investors on Thursday,Benzinga reports. The firm presently has an "overweight" rating on the medical research company's stock. Barclays's target price points to a potential upside of 18.07% from the stock's current price.

A number of other equities analysts also recently commented on EW. JPMorgan Chase & Co. lifted their price objective on Edwards Lifesciences from $72.00 to $78.00 and gave the stock a "neutral" rating in a research report on Friday, October 25th. Evercore ISI reduced their price objective on Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating on the stock in a research report on Wednesday, February 12th. Morgan Stanley lifted their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an "equal weight" rating in a research report on Wednesday, February 12th. Sanford C. Bernstein upgraded Edwards Lifesciences from a "strong sell" rating to a "hold" rating in a research report on Monday, October 28th. Finally, Robert W. Baird reduced their target price on Edwards Lifesciences from $73.00 to $68.00 and set a "neutral" rating on the stock in a research report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $79.95.

Edwards Lifesciences Price Performance

EW traded up $0.23 during trading on Thursday, hitting $76.23. The company's stock had a trading volume of 3,899,190 shares, compared to its average volume of 4,438,355. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The business's fifty day simple moving average is $72.67 and its 200 day simple moving average is $69.58. The firm has a market capitalization of $44.96 billion, a price-to-earnings ratio of 11.00, a P/E/G ratio of 3.64 and a beta of 1.10. Edwards Lifesciences has a twelve month low of $58.93 and a twelve month high of $96.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. On average, equities research analysts forecast that Edwards Lifesciences will post 2.56 EPS for the current fiscal year.

Insider Buying and Selling

In other Edwards Lifesciences news, Director Steven R. Loranger sold 5,739 shares of the stock in a transaction on Friday, February 14th. The stock was sold at an average price of $76.42, for a total transaction of $438,574.38. Following the transaction, the director now owns 60,372 shares of the company's stock, valued at $4,613,628.24. This represents a 8.68 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total value of $852,300.00. Following the transaction, the chief financial officer now directly owns 30,561 shares in the company, valued at approximately $2,315,301.36. This represents a 26.91 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 26,489 shares of company stock worth $2,002,829 in the last quarter. Company insiders own 1.29% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Crowley Wealth Management Inc. purchased a new position in shares of Edwards Lifesciences in the 4th quarter worth $26,000. Millstone Evans Group LLC purchased a new position in shares of Edwards Lifesciences in the 4th quarter worth $29,000. FSA Wealth Management LLC purchased a new position in shares of Edwards Lifesciences in the 3rd quarter worth $30,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of Edwards Lifesciences in the 4th quarter worth $30,000. Finally, Prospera Private Wealth LLC purchased a new position in shares of Edwards Lifesciences in the 3rd quarter worth $32,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.